Sofdra earns International Hyperhidrosis Society Seal of Recognition
Botanix Pharmaceuticals (ASX:BOT) announced on 10 November 2026 that Sofdra® (sofpironium) topical gel, 12.45% is a recipient of the International Hyperhidrosis Society (IHhS) Seal of Recognition™. According to the company, this is the first time in 20 years that the recognition has been awarded.
IHhS is a US-based non-profit organisation dedicated to people living with hyperhidrosis, or excessive sweating. With the award, Sofdra is “Recognized by the International Hyperhidrosis Society for Research & Rigor in Helping Combat Excessive Sweating™.”
The award highlights products, devices and procedures validated by:
- Strong scientific and clinical evidence
- Rigorous testing
- Demonstrated efficacy and tolerability
- Responsible marketing communications
For investors, the recognition is independent validation of Sofdra’s evidence base and marketing conduct.
Independent validation of the evidence base sits alongside a widening intellectual property estate, with a recent US patent allowance covering the crystalline form of the drug substance and protection running into May 2040.
Dr Howie McKibbon, Chief Executive Officer, Botanix
“…IHhS has long been the champion of people living with hyperhidrosis, so this recognition carries real meaning for Botanix.”
When big ASX news breaks, our subscribers know first
Hyperhidrosis Awareness Month support in dermatology offices
The recognition arrives at the start of Hyperhidrosis Awareness Month, which IHhS has led each November. Botanix is supporting the month with:
- Increased promotion in dermatology offices to raise awareness of primary axillary hyperhidrosis (excessive underarm sweating) and Sofdra
- New materials placed in physicians’ waiting areas and exam rooms
- Materials designed to help patients self-identify their condition and prompt conversations between physicians and patients
Hyperhidrosis affects more than 16 million Americans, according to the company. Many people do not recognise it as a medical condition, and only around half raise it with their doctor.
Botanix describes Sofdra as the first and only new chemical entity approved by FDA to treat primary axillary hyperhidrosis.
On the cost side, a second API supplier under a Piramal term sheet is intended to lower cost of goods sold and reduce reliance on a single manufacturing partner as volumes grow.
Get Healthcare News Before the Market Moves
Get FREE breaking ASX healthcare news delivered to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ subscribers already staying ahead of the market. Click the “Free Alerts” button at Big News Blast to receive the next market-moving announcement the moment it breaks.